Fluorescence cystoscopy: Is it ready for use in routine clinical practice?

Current Opinion in Urology

Volumn 16, Issue 5, 2006, Pages 372-376

  Spiess, Philippe E ^a   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bladder cancer; Cystoscopy; Fluorescence

Indexed keywords

FLUORESCENT DYE;

BLADDER CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLUORESCENCE CYSTOSCOPY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION;

CYSTOSCOPY; DIAGNOSTIC TESTS, ROUTINE; FLUORESCENT DYES; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 33747186436     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000240312.16324.9a     Document Type: Review

References (35)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004; 54:8-29.
2. Kurth KH. Natural history and prognosis of untreated and treated superficial bladder cancer. In: Pagano F, Fair WR, editors. Superficial bladder cancer. Oxford: Isis Medical Media; 1997. pp. 42-56.
3. Joudi FN, Konety BR. Fluorescence cystoscopy and bladder surveillance. Curr Opin Urol 2004; 14:265-270.
4. Zaak D, Karl A, Knuchel R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005; 96:217-222.
5. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology 2002; 60:1025-1028.
6. Schellhammer PF. Immediate adjuvant intravesical chemotherapy after transurethral resection of the bladder. Curr Opin Urol 1998; 8:407-409.
7. Jocham D, Baumgartner R, Fuchs N, et al. Fluorescence diagnosis of porphyrin-marked urothelial tumors. Status of experimental development. Urologe A 1989; 28:59-64.
8. Koenig F, McGovern FJ. Fluorescence detection of bladder carcinoma. Urology 1997; 50:778-779.
9. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155:105-109.
10. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001; 57:690-694.
11. Zaak D, Hungerhuber E, Schneede P, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002; 95:1234-1238.
12. Hungerhuber E, Kriegmair M, Knuechel R, et al. Seven years detection of bladder cancer with 5-ALA - results of 1713 fluorescence endoscopies [abstract 863]. J Urol 2004; 169:223.
13. Steinbach P, Weingandt H, Baumgartner R, et al. Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol 1995; 62:887-895.
14. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003; 170:428-432.
15. Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999; 80:185-193.
16. Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206. Drugs R D 2005; 6:235-238.
17. Fotinos N, Campo MA, Popowycz F, et al. 5-Aminolevulinic acid derivatives in photomedicine: basics, application, and perspectives. Photochem Photobiol 2006 [Epub ahead of print].
18. Lavie G, Mazur Y, Lavie D, et al. The chemical and biological properties of hypericin - a compound with a broad spectrum of biological activities. Med Res Rev 1995; 15:111-119.
19. Yamazaki T, Ohta N, Yamazaki I, et al. Excited state properties of hypericin: electronic spectra and fluorescence decay kinetics. J Phys Chem 1993; 97:7870-7875.
20. Filbeck T, Wimmershoff MB, Pichlmeier U, et al. No generalized skin phototoxicity after intravesical application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer. Urol Int 2000; 64:126-128.
21. Popken G, Schultze-Seemann W, Seiler KU, et al. Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. Eur J Clin Pharmacol 2000; 56:241-246.
22. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003; 170:226-229.
23. Grimbergen MC, van Swol CF, Jonges TG, et al. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003; 44:51-56.
24. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174:862-866. Multicenter, prospective phase III study demonstrating the improved detection and treatment of bladder cancer using hexaminolevulinate fluorescence cystoscopy compared with conventional white light cystoscopy.
25. Grossman HB, Gomella LG, Fradet Y, et al. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder [abstract 263]. J Urol 2004; 171:69.
26. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171:135-138.
27. D'Hallewin MA, Kamuhabwa AR, Roskams T, et al. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 2002; 89:760-763.
28. Sim HG, Lau WK, Olivo M, et al. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int 2005; 95:1215-1218. Prospective study evaluating the improved sensitivity and specificity for bladder cancer detection using hypericin fluorescence compared with white light cystoscopy.
29. Loidl W, Schmidbauer J, Susani M, et al. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 2005; 47:323-326. Prospective, phase II study evaluating and demonstrating the comparable ability of flexible and rigid fluorescence cystoscopies in detecting papillary and flat lesions in bladder cancer patients.
30. Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol 2005; 47:319-322. Prospective, phase II study showing the feasibility of performing flexible fluorescence cystoscopy in clinical practice with cancer detection rates comparable to white light cystoscopy, although slightly inferior to rigid fluorescence cystoscopy.
31. Zlotta A. Fluorescence cystoscopy: is flexible scope as effective as rigid? Eur Urol 2005; 47:318. Editorial summarizing the results of recent trials on fluorescence cystoscopy and evaluating the relative performance of flexible and rigid fluorescence cystoscopies.
32. Babjuk M, Soukup V, Petrik R, et al. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96: 798-802. Recent prospective study showing the reduced short-term recurrence risk in performing transurethral resection of Ta/T1 bladder tumors under fluorescence compared with white light cystoscopy.
33. Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174:2129-2133. Recent randomized prospective study showing the reduced long-term recurrence and tumor progression risk with ALA-assisted TUR for suspected superficial bladder tumors.
34. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168:67-71.
35. Stenzl A, Holtl L, Bartsch G. Fluorescence assisted transurethral resection of bladder tumours: is it cost effective? Eur Urol 2001; 39:31.